Clinical relevance of apoptotic markers in breast cancer not yet clear

Apoptosis

Volumn 7, Issue 4, 2002, Pages 361-365

  Jager, J J ^a   Jansen, R L H ^b   Arends, J W ^c  

^a MAASTRO CLINIC   (Netherlands)

^b MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^c DEVENTER HOSPITAL   (Netherlands)

Author keywords

Apoptosis; Apoptotic index; bcl 2; Breast cancer; p53; Prognosis

Indexed keywords

ESTROGEN; ESTROGEN RECEPTOR; MOLECULAR MARKER; PROTEIN BCL 2; PROTEIN P53; TUMOR MARKER; BCL2 ASSOCIATED ATHANOGENE 1 PROTEIN; BCL2-ASSOCIATED ATHANOGENE 1 PROTEIN; CARRIER PROTEIN; DNA BINDING PROTEIN; TRANSCRIPTION FACTOR;

APOPTOSIS; BREAST CANCER; CANCER GRADING; OUTCOMES RESEARCH; PATIENT SELECTION; PRIORITY JOURNAL; PROGNOSIS; REVIEW; TUMOR GROWTH; TUMOR VOLUME; BREAST TUMOR; FEMALE; FORECASTING; GENETIC MARKER; GENETICS; HUMAN; PATHOLOGY; PATHOPHYSIOLOGY; PROTO ONCOGENE; TREATMENT OUTCOME;

APOPTOSIS; BREAST NEOPLASMS; CARRIER PROTEINS; FEMALE; FORECASTING; GENES, BCL-2; GENETIC MARKERS; HUMAN; PROTEIN P53; TREATMENT OUTCOME; DNA-BINDING PROTEINS; HUMANS; TRANSCRIPTION FACTORS; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0036022406     PISSN: 13608185     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1016179530785     Document Type: Review

References (51)

1. Clinical studies of bcl-2 and treatment benefit in breast cancer patients
2. Prognostic significance of apoptosis regulators in breast cancer
3. C-myc, p53, bcl-2, apoptosis-related genes in infiltrating breast carcinoma: Evidence of a link between bcl-2 protein over-expression and a lower risk of metastasis in breast cancer patients
4. Apoptosis in breast carcinoma
5. Apoptosis and cell proliferation in medullar carcinoma of the breast: A comparative study between medullary and non-medullary carcinoma using TUNEL and IHC
6. Bcl-2, p53 and clinical outcome in a series of 138 operable breast cancer patients
7. C-erbB-2 expression and response to adjuvant therapy in women with node-positive early breast cancer
8. Number of apoptotic cells as a prognostic marker in invasive breast cancer
9. Synergistic cooperation between cMyc and bcl-2 in lymph node progression of T1 human breast carcinomas
10. Apoptosis in breast cancer and its relationship to clinicopathological characteristics and prognosis
11. Mutations in exon 5-8 of the p53 gene, independent of their type and location, are associated with increased apoptosis and mitosis in invasive breast cancer
12. Expression of survivin and its relationship to loss of apoptosis in breast carcinomas
13. Overview on human breast cancer with focus on prognostic and predictive factors with special attention on the tumour suppressor gene p53
14. Prognostic and predictive value of p53 and p21 in breast cancer
15. Bcl-2, p53 and response to tamoxifen in estrogen receptor-positive metastatic breast cancer: A Southwest Oncology Group study
16. P53 protein accumulation predicts poor response to tamoxifen therapy of patients with recurrent breast cancer
17. Expression of ras p21, p53 and c-erbB2 in advanced breast cancer and response to first line hormonal therapy
18. Predictive value of c-erbB-2, p53, cathepsin-D and histology of the primary tumour in matastatic breast cancer
19. No significant predictive value of c-erbB-2 or p53 expression regarding sensitivity to primary chemotherapy or radiotherapy in breast cancer
20. P53 protein accumulation and response to adjuvant chemotherapy in premenopausal women with node-negative early breast cancer
21. Primary systemic teatment with weekly doxorubicin monotherapy in women with locally advanced breast cancer; Clinical experience and parameters predicting outcome
22. Tp 53 mutation and p53 overexpression for prediction of response to neoadjuvant treatment in breast cancer patients
23. p53 gene status and response to platinum/paclitaxel-based chemotherapy in advanced ovarian carcinoma
24. The Bcl-2 protein: A prognostic indicator strongly related to p53 protein in node negative breast cancer
25. Prognostic value of bcl-2 expression in invasive breast cancer
26. Apoptosis suppressing protein bcl-2 is expressed in well-differentiated breast cancer with favourable prognosis
27. Bcl-2 protein expression and long-term survival in breast cancer
28. The expression of Ki-S1 and BCL-2 and the response to primary tamoxifen therapy in elderly patients with breast cancer
29. Immunocytochemical localization of bcl-2 protein in human breast cancer to a series of prognostic markers and response to endocrine therapy
30. P53 and bcl-2 expression correlates with clinical outcome in a series of node-positive breast cancer patients
31. Clinical significance of bcl-2 gene expression in human breast cancer tissues
32. Bcl-2 protein in invasive ductal breast carcinomas
33. P53 but not bcl-2 immunostaining is predictive of poor clinical complete response to primary chemotherapy in breast cancer patients
34. Primary chemotherapy in locally advanced breast cancer (LABC): Effects on turnout proliferative activity, bcl-2 expression and the relationship between turnout regression and biological markers
35. Reduced apoptosis and proliferation and increased bcl-2 in residual breast cancer following preoperative chemotherapy
36. Biological markers as indicators of response to primary and adjuvant chemotherapy in breast cancer
37. Expression of bcl-2 in node-negative breast cancer is associated with various prognostic factors, but does not predict respons to one course of perioperative chemotherapy
38. Expression of bcl-2 protein predicts efficacy of adjuvant treatments in operable node-positive breast cancer
39. Analysis of Bax and Bcl-2 expression in p53-immunopositive breast cancers
40. Expression of Bag-1 in invasive breast carcinomas
41. BAG-1: A novel biomarker predicting long-term survival in early-stage breast cancer
42. Bax immunohistochemical expression in breast carcinoma: A study with long term follow-up
43. Can expression of apoptosis genes, bcl-2 and bax, predict survival and responsiveness to chemotherapy in node-negative breast cancer patients?
44. A multivariate analysis of tumour biological factors predicting response to cytotoxic treatment in advanced breast cancer
45. Circulating soluble Fas concentration in breast cancer patients
46. Anti-apoptotic phenotype is associated with decreased locoregional recurrence rate in breast cancer
47. Radiation-induced apoptosis: Relevance to radiotherapy
48. Key targets for the execution of radiation-induced tumor cell apoptosis: The role of p53 and caspases
49. Apoptosis, p53, and tumor cell sensitivity to anticancer agents
50. Evidence against apoptosis as a major mechanism for reproductive cell death following treatment of cell lines with anti-cancer drugs